Critical

Severe Legionnaires’ disease

Atypical pneumonia · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pneumonia caused by Legionella pneumophila (waterborne; aerosol exposure). Although only ~5% of community-acquired pneumonia, it is a leading cause of CAP requiring ICU — roughly a third are admitted to intensive care and mortality reaches ~40% in ICU, immunocompromised or hospital-acquired cases. Suspect it in severe pneumonia with extrapulmonary clues.

Red flags

  • Severe hypoxaemia / progression to ARDS
  • Septic shock, multi-organ failure
  • Immunocompromise or nosocomial acquisition (higher mortality)
  • Rapidly extending consolidation
  • Rhabdomyolysis / AKI

Assessment

Differential diagnosis

  • Pneumococcal / other bacterial CAP
  • Viral pneumonia (influenza, COVID-19)
  • Other atypicals (Mycoplasma, Chlamydophila)
  • Aspiration pneumonia
  • ARDS from another cause

Investigations

  • Legionella URINARY ANTIGEN (detects L. pneumophila serogroup 1) + lower-respiratory PCR/culture (detects all serogroups)
  • CXR/CT (patchy → dense consolidation, may progress rapidly)
  • FBC, U&E (HYPONATRAEMIA is a clue), LFTs (transaminitis), CRP/procalcitonin, CK (rhabdomyolysis), lactate, blood cultures
  • ABG; assess for ARDS and organ failure

Management

  • Assess severity (CURB-65 / sepsis) and resuscitate; high-flow oxygen; escalate early — severe LD deteriorates fast.
  • Start EFFECTIVE ANTI-LEGIONELLA therapy promptly: a respiratory FLUOROQUINOLONE (levofloxacin or moxifloxacin) OR a macrolide (azithromycin).
  • For SEVERE disease (ICU / immunocompromised): use COMBINATION therapy (a fluoroquinolone plus a macrolide, or plus rifampicin) and treat for a PROLONGED course — typically 7–10 days, extended (up to ~21 days) in the immunocompromised or slow responders.
  • Full sepsis bundle: cultures, lactate, fluids, source consideration; supportive organ support.
  • Lung-protective ventilation for ARDS; manage AKI, hyponatraemia, rhabdomyolysis and other organ dysfunction.
  • Notify public health and investigate the water source (institutional outbreaks); review the empirical CAP regimen to ensure Legionella cover in severe cases.

Drugs & doses

Levofloxacin or moxifloxacin (respiratory fluoroquinolone) — first-line
Azithromycin (macrolide) — alternative or combination partner
Severe/immunocompromised: fluoroquinolone + macrolide (or + rifampicin), prolonged course
Oxygen; IV fluids; vasopressors as needed for septic shock

Disposition

Admit; ICU for severe hypoxaemia, shock or organ failure. Notify public health; ensure water-source investigation for possible outbreaks.

Complications & pitfalls

  • ARDS and respiratory failure
  • Septic shock, multi-organ failure
  • AKI, rhabdomyolysis
  • Hyponatraemia; hepatic dysfunction
  • Death (up to ~40% in ICU cohorts)

Exam pearls

  • Severe pneumonia + hyponatraemia + deranged LFTs + diarrhoea/confusion → think Legionella and send the urinary antigen.
  • Empirical CAP cover for severe/ICU pneumonia must include an anti-Legionella agent.
  • Urinary antigen catches only serogroup 1 — add lower-respiratory PCR/culture if suspicion is high.
  • Severe cases need combination therapy and a longer course.

Suspect Legionella in severe CAP with extrapulmonary features; confirm with urinary antigen + respiratory PCR; treat promptly with a fluoroquinolone or macrolide — combination and prolonged therapy for severe/immunocompromised disease — alongside full sepsis and ARDS care.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.